
Intrinsic Therapeutics introduced the Barricaid Narrow Anchor, the next generation of its FDA PMA-approved Barricaid Bone-Anchored Annular Closure Device. The new version of the Barricaid device is 25% smaller than the standard Barricaid anchor.
This updated device is designed to make implantation easier by reducing bony removal and nerve root retraction, thus increasing the number of high-risk patients who can benefit from a reduction in reherniation and reoperation after discectomy.
The Narrow Anchor reduces the bone anchor width from 8mm to 6mm, a change driven by surgeon feedback to improve ease of implantation. Potential benefits include:
- Reduced Retraction: Spine simulator measurements demonstrated a 25% to 40% reduction in nerve root retraction during implantation.
- Enhanced Visibility: Optimized anchor geometry improves a surgeon’s view during placement.
- Easy to Implant: 95% of surgeons reported that the Narrow Anchor device was easy to implant.
Despite the smaller footprint, the device passed the same mechanical testing criteria as the original 8mm anchor, including resistance to anchor migration and fracture.
The Narrow Anchor launch follows recent momentum for Barricaid, including the American Medical Association’s release of the 2026 CPT Code Set, which includes new CPT code 63032 describing bone-anchored annular closure, effective January 1, 2026.
Source: Intrinsic Therapeutics, Inc.
Intrinsic Therapeutics introduced the Barricaid Narrow Anchor, the next generation of its FDA PMA-approved Barricaid Bone-Anchored Annular Closure Device. The new version of the Barricaid device is 25% smaller than the standard Barricaid anchor.
This updated device is designed to make implantation easier by reducing bony removal and nerve...
Intrinsic Therapeutics introduced the Barricaid Narrow Anchor, the next generation of its FDA PMA-approved Barricaid Bone-Anchored Annular Closure Device. The new version of the Barricaid device is 25% smaller than the standard Barricaid anchor.
This updated device is designed to make implantation easier by reducing bony removal and nerve root retraction, thus increasing the number of high-risk patients who can benefit from a reduction in reherniation and reoperation after discectomy.
The Narrow Anchor reduces the bone anchor width from 8mm to 6mm, a change driven by surgeon feedback to improve ease of implantation. Potential benefits include:
- Reduced Retraction: Spine simulator measurements demonstrated a 25% to 40% reduction in nerve root retraction during implantation.
- Enhanced Visibility: Optimized anchor geometry improves a surgeon’s view during placement.
- Easy to Implant: 95% of surgeons reported that the Narrow Anchor device was easy to implant.
Despite the smaller footprint, the device passed the same mechanical testing criteria as the original 8mm anchor, including resistance to anchor migration and fracture.
The Narrow Anchor launch follows recent momentum for Barricaid, including the American Medical Association’s release of the 2026 CPT Code Set, which includes new CPT code 63032 describing bone-anchored annular closure, effective January 1, 2026.
Source: Intrinsic Therapeutics, Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





